Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.

The owner and original poster (OP), username LittleBucket07, who brought their 12-week-old Labrador for booster shots, took ...

Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...

A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022. The study evaluated vaccine ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Merck , known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the ...

Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.